BR112014009141A2 - regime de dosagem para um modulador ou agonista do receptor s1p - Google Patents

regime de dosagem para um modulador ou agonista do receptor s1p

Info

Publication number
BR112014009141A2
BR112014009141A2 BR112014009141A BR112014009141A BR112014009141A2 BR 112014009141 A2 BR112014009141 A2 BR 112014009141A2 BR 112014009141 A BR112014009141 A BR 112014009141A BR 112014009141 A BR112014009141 A BR 112014009141A BR 112014009141 A2 BR112014009141 A2 BR 112014009141A2
Authority
BR
Brazil
Prior art keywords
agonist
dosage regimen
receptor modulator
human
patient
Prior art date
Application number
BR112014009141A
Other languages
English (en)
Other versions
BR112014009141A8 (pt
Inventor
Wallstroem Erik
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47022722&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112014009141(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR112014009141A2 publication Critical patent/BR112014009141A2/pt
Publication of BR112014009141A8 publication Critical patent/BR112014009141A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/32—Oximes
    • C07C251/34—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C251/48—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with the carbon atom of at least one of the oxyimino groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

resumo patente de invenção: "regime de dosagem para um modulador ou agonista do receptor s1p". a presente invenção refere-se a um método de tratamento de esclerose múltipla em um paciente mamífero, de preferência um ser humano, em necessidade de tal tratamento, compreendendo a administração ao referido ser humano de um modulador ou agonista do receptor s1p de acordo com um regime de dosagem que é determinado com referência à contagem de linfócitos no sangue do paciente.
BR112014009141A 2011-10-21 2012-10-18 regime de dosagem para um modulador ou agonista do receptor s1p BR112014009141A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161549847P 2011-10-21 2011-10-21
PCT/EP2012/070692 WO2013057212A1 (en) 2011-10-21 2012-10-18 Dosage regimen for an s1p receptor modulator or agonist

Publications (2)

Publication Number Publication Date
BR112014009141A2 true BR112014009141A2 (pt) 2017-06-13
BR112014009141A8 BR112014009141A8 (pt) 2017-06-20

Family

ID=47022722

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014009141A BR112014009141A8 (pt) 2011-10-21 2012-10-18 regime de dosagem para um modulador ou agonista do receptor s1p

Country Status (17)

Country Link
US (1) US20150218090A1 (pt)
EP (1) EP2768494A1 (pt)
JP (1) JP2014530835A (pt)
KR (1) KR20140084041A (pt)
CN (1) CN103889408A (pt)
AU (1) AU2012324867B2 (pt)
BR (1) BR112014009141A8 (pt)
CA (1) CA2852142A1 (pt)
CL (1) CL2014000991A1 (pt)
IL (1) IL231945A0 (pt)
MX (1) MX2014004813A (pt)
RU (1) RU2014120411A (pt)
SG (2) SG10201602279PA (pt)
TN (1) TN2014000132A1 (pt)
TW (1) TW201320998A (pt)
WO (1) WO2013057212A1 (pt)
ZA (1) ZA201402283B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2943598C (en) * 2014-04-10 2023-03-07 Novartis Ag S1p modulator immediate release dosage regimen
EP3168237A1 (en) * 2015-11-10 2017-05-17 Dow Global Technologies LLC High pressure, free radical polymerizations to produce ethylene-based polymers
US11629124B2 (en) 2017-03-09 2023-04-18 Novartis Ag Solid forms comprising an oxime ether compound, compositions and methods of use thereof
MX2022005014A (es) 2019-10-31 2022-05-16 Idorsia Pharmaceuticals Ltd Combinacion de un antagonista de cxcr7 con un modulador del receptor s1p1.
US20230295076A1 (en) * 2020-08-20 2023-09-21 Medshine Discovery Inc. Acetophenone oxime compound and application thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL372103A1 (en) 2002-05-16 2005-07-11 Novartis Ag Use of edg receptor binding agents in cancer
CA2524048C (en) 2003-05-19 2013-06-25 Irm Llc Immunosuppressant compounds and compositions
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
CN1791395B (zh) * 2003-05-19 2012-09-26 Irm责任有限公司 免疫抑制剂化合物及组合物
UA74941C2 (en) 2004-04-26 2006-02-15 Fos Internat S A A metal-thermal process for producing magnesium and vacuum induction furnace for realizing the same
KR20150028858A (ko) * 2004-11-29 2015-03-16 노파르티스 아게 Ｓ１ｐ 수용체 효능제의 투여 용법
GB0612721D0 (en) * 2006-06-27 2006-08-09 Novartis Ag Organic compounds
ES2545361T3 (es) * 2007-10-12 2015-09-10 Novartis Ag Composiciones que comprenden moduladores del receptor de esfingosina 1-fosfato (S1P)
SG171888A1 (en) * 2008-12-22 2011-07-28 Novartis Ag Dosage regimen of an s1p receptor agonist
CA3129729A1 (en) * 2009-09-29 2011-04-07 Novartis Ag Dosage regimen of an s1p receptor modulator

Also Published As

Publication number Publication date
MX2014004813A (es) 2014-05-20
US20150218090A1 (en) 2015-08-06
SG11201401065RA (en) 2014-09-26
CA2852142A1 (en) 2013-04-25
RU2014120411A (ru) 2015-11-27
TN2014000132A1 (en) 2015-07-01
EP2768494A1 (en) 2014-08-27
SG10201602279PA (en) 2016-04-28
NZ623571A (en) 2016-03-31
IL231945A0 (en) 2014-05-28
ZA201402283B (en) 2015-03-25
CL2014000991A1 (es) 2014-08-22
CN103889408A (zh) 2014-06-25
KR20140084041A (ko) 2014-07-04
AU2012324867B2 (en) 2015-09-10
JP2014530835A (ja) 2014-11-20
TW201320998A (zh) 2013-06-01
WO2013057212A1 (en) 2013-04-25
BR112014009141A8 (pt) 2017-06-20
AU2012324867A1 (en) 2014-05-08

Similar Documents

Publication Publication Date Title
BR112014008731A2 (pt) tratamento de esclerose múltipla com combinação de laquinimode e fingolimode
BR112013027554A2 (pt) "usos de compostos no tratamento de mal de alzheimer, doença de huntington, autismo e outros distúrbios"
AR097178A1 (es) Diagnóstico y terapias anticáncer que comprenden células madre cancerosas
BR112015006623A2 (pt) laquinimod e pridopidina para o tratamento de doenças neurodegenerativas
MY175997A (en) Antl-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig protein scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition
BR112014010803A2 (pt) método de tratamento
EA201590654A1 (ru) Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона
BR112012005225B8 (pt) Uso de uma proteína de fusão actriib-fc para o tratamento de um transtorno relacionado ao osso ou associado à perda de músculo por crescimento muscular insuficiente
JP2016518387A5 (pt)
BR112015022197A8 (pt) uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia
BR112014009785A8 (pt) método para tratar ou reduzir efp
BR112015009503A2 (pt) dispostivo de tratamento extracorporal do sangue
BR112014009141A2 (pt) regime de dosagem para um modulador ou agonista do receptor s1p
BR112014018485A8 (pt) Uso de laquinimod para tratar pacientes com a doença de crohn que falharam com a primeira linha de terapia anti-tnf
MX2022010357A (es) Anticuerpos inhibidores de anti-pcsk9 para el tratamiento de pacientes con hiperlipidemia que se someten aferesis de lipoproteina.
CL2013003298A1 (es) Uso de metotrexato porque sirve para preparar un medicamento, útil en el tratamiento de enfermedades que necesiten tratamiento con un producto terapéutico que produzca autoinmunidad, administrado en un sólo ciclo.
BR112015007782A2 (pt) laquinimod para reduzir danos talâmicos na esclerose múltipla
BR112013020586A2 (pt) Uso de células derivadas de tecido do cordão umbilical
BR112013031117A8 (pt) Scilo-inositol para o tratamento de transtornos comportamentais e psiquiátricos.
BR112014019399A2 (pt) métodos de tratamento da fibrose
BR112016028446A2 (pt) inibidor de complemento de ornithodoros moubata para uso no tratamento de doenças mediadas por complemento em pacientes com polimorfismo de c5
CO2017008395A2 (es) Inhalador de polvo seco que comprende propionato de fluticasona y xinafoato de salmeterol
BR112015000808A2 (pt) regime de dosagem para inibidores de janus quinase (jak)
BR112017006272A2 (pt) composição farmacêutica para tratar colite ulcerativa.
BR112014011223A2 (pt) método de tratar uma doença proliferativa

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2484 DE 14-08-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B350 Update of information on the portal [chapter 15.35 patent gazette]